WWW.IJRPR.COM

International Journal of Research Publication and Reviews

Journal homepage: www.ijrpr.com ISSN 2582-7421

Antibiotics in Children: A Comprehensive Review

Dr. Ashwini Jadhav[1] Krushna P. Kale[2], Sujal K. Kadam [3], Dr Tushar Shelke[4],

[1].Associate professor, Genba Sopanrao Moze College of Pharmacy, Wagholi, Pune 412207 Maharashtra, India
[2,3] Research Scholar, Genba Sopanrao Moze College of Pharmacy, Wagholi, Pune 412207 Maharashtra, India
[4] Principal, Genba Sopanrao Moze College of Pharmacy, Wagholi , Pune 412207 Maharashtra, India
E. mail: avj.gsmcop@gmail.com

ABSTRACT

Antibiotics are valuable in the management of bacterial infections in children, but prescribing doctors must also consider physiological differences across age groups and the potential adverse effects from antibiotics and other medications. Antimicrobial resistance is an increased concern in 2023, and this review focuses on some common pediatric infections, the antibiotics used to treat these infections, and dose considerations, safety concerns, and antimicrobial resistance. Furthermore, we discuss antimicrobial stewardship programs and special considerations for pediatric patients, including neonates and immune compromised children. Finally, we discuss considerations for upcoming innovations in the pediatric treatment of infection. The goal of this review is to equip healthcare providers with information to optimize antibiotic use with effectiveness, safety, and antimicrobial resistance stewardship in mind in the pediatric population.[1,2]

KEY WORDS: Antibiotics, pediatric, bacterial infections, antimicrobial resistance

INTRODUCTION

[1,2]Antibiotics are essential medications in pediatrics and have changed the management of bacterial infections that were once life-threatening. Children, particularly neonates and infants, are vulnerable to infection due to their immature immune systems. The pharmacology and usage of antibiotics in neonates, infants, and children is further complicated by their lack of overlapping physiology with adults. The factors that differ include gastric pH, gastric emptying time, enzyme activity, body water and fat composition, maturity of renal and hepatic mechanisms, and microbiome development.

Antibiotics are used to treat many different infections—ranging from the common respiratory tract infections such as otitis media and community-acquired pneumonia to more severe infections such as neonatal sepsis and meningitis. Appropriate antibiotic selection is critical in order to optimize efficacy of treatment, minimize adverse effects, and prevent the development of, and protect against antibiotic resistant strains of microorganisms.

Although antibiotics are helpful in treating bacterial infections in children and neonates, potential side effects are present. They include: gastrointestinal upset, allergic reactions, nephrotoxicity, hepatotoxicity, and microbiome upset. Inappropriate use, or overprescribe, of antibiotics can contribute to antimicrobial resistance (AMR), an ongoing and growing threat worldwide. Pediatric stewardship programs have risen to prominence in safeguarding judicious use of antibiotics.

This paper is a thorough review of a variety of commonly prescribed antibiotics used in children, providing their pharmacology, indications, dosing considerations, adverse effects, resistance concerns, and clinical guidance.

Common Pediatric Infections

[3] Children are especially susceptible to infections due immature immune systems and exposure in schools, daily routine , and other community settings. Common infections to children include:

Respiratory tract infections (RTIs): Respiratory infections are among the leading causes of morbidity in children. Otitis media (middle ear infection) is common in infants and young children and typically presents with ear pain, fever, and irritability. Community-acquired pneumonia (CAP) is another common RTI that ranges in severity from mild to severe. Symptoms include cough, fever, difficulty breathing (dyspnea), chest pain, and/or fast breathing. Organisms responsible for RTIs include Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis, as well as atypical bacteria such as Mycoplasma pneumoniae and Chlamydia pneumoniae. If a child's condition worsens, timely administration of an antibiotic may prevent complications from pneumonia, such as mastoiditis, empyema, or bacteremia.

[4]Urinary tract infections (UTIs): UTIs are common childhood bacterial infections, particularly among female children and uncircumcised boys. These infections usually present with fever, dysuria, frequency, urgency, abdominal pain, and/or hematuria. The most common pathogenic bacteria in pediatric UTIs is Escherichia coli (E. coli); other common pathogens include Klebsiella and Proteus species. If UTIs are untreated, complications can

arise, including pyelonephritis, renal scarring, and long-term kidney dysfunction. It is important to assess a child's clinical status and provide appropriate antibiotic therapy quickly to avoid the serious complications of UTI.

[5]**Skin and Soft Tissue Infections (SSTIs):** Conditions of the skin such as impetigo, cellulitis, and abscesses are commonly seen in children because of minor cuts, bee stings, or other minor injury to the skin. The most common pathogen in these are Staphylococcus aureus (including MRSA) and Streptococcus pyogenes. Clinical features include: redness, swelling, tenderness, warmth, and possibly purulent drainage. It is important to select the appropriate antibiotic and manage the wound to avoid systemic infections or sequential additional resistance to antibiotics.

Severe and Invasive Infections: Neonatal sepsis is a life-threatening infection in newborns. The infectious sources are often group B strep, E. coli, and Listeria monocytogenes. The early signs for sepsis can be nonspecific - like lethargy, poorly feeding, and temperature instability. Meningitis is another sever infection that occurs mostly in neonates and infants. The most common pathogens are Neisseria meningitis, S. pneumoniae, and Hemophilus influenzae type b (Hib). It is imperative to recognize and start empiric intravenous antibiotics promptly for survival and to help prevent neurological problems.

Gastrointestinal Infections: Bacterial gastroenteritis caused by Salmonella, Shigella, Campylobacter, or other pathogens, can cause dehydration and electrolyte imbalance in children. Symptoms are usually fever, vomiting, diarrhea and abdominal cramps. Antibiotic treatment is usually left for severe cases, infants, and those who are immunocompromised.

Ear, Nose, and Throat Infections: Pharyngitis, tonsillitis, and sinusitis are common, and often caused by Streptococcus pyogenes or H. influenzae. Complications of untreated streptococcal disease can occur, including rheumatic fever or post-streptococcal glomerulonephritis. In general, these infections require accurate diagnosis, selection and monitoring of antibiotics to avoid complications of the infections and the development of antimicrobial resistance. As we discussed in this chapter, early intervention and preventive methods (eg, vaccines, hygiene) are important aspects of the pediatric care



Figure no.1: Pharmacokinetics of antibiotics in pediatric and neonatal intensive care

CLASSES OF ANTIBIOTICS IN PEDIATRICS

[6,7]Antibiotics are classified based on their mechanism of action, spectrum of activity, and chemical structure. Understanding the different classes is essential for selecting the appropriate therapy for pediatric patients. Each class has unique pharmacological properties, indications, and considerations for safety and efficacy.

Penicillins:

[8]Penicillins are beta-lactam antibiotics that inhibit bacterial cell wall synthesis, leading to bacterial death. They are widely used in children due to their broad-spectrum activity, safety, and proven efficacy.

Common Drugs: Amoxicillin, Amoxicillin-Clavulanate, Benzylpenicillin (Penicillin G), Phenoxymethylpenicillin (Penicillin V).

Indications: Otitis media, community-acquired pneumonia, streptococcal pharyngitis, skin infections, urinary tract infections.

Pharmacokinetics: Absorbed orally (except Benzylpenicillin), widely distributed, primarily excreted by the kidneys.

Adverse Effects: Allergic reactions (ranging from rash to anaphylaxis), gastrointestinal upset, diarrhea, and rarely hematologic effects.

Special Considerations: Monitor for allergy history; amoxicillin is preferred for high-dose therapy in severe infections.

Cephalosporins:

[9]Cephalosporins are beta-lactam antibiotics structurally related to penicillins. They act by inhibiting bacterial cell wall synthesis and are grouped into generations based on their antimicrobial spectrum.

Common Drugs: Ceftriaxone, Cefotaxime, Cephalexin, Cefuroxime.

Indications: Severe infections such as meningitis, pneumonia, UTIs, skin infections, and surgical prophylaxis.

Pharmacokinetics: Well, absorbed orally (for some agents), extensively distributed, renal elimination predominates.

Adverse Effects: Gastrointestinal upset, hypersensitivity reactions, rare hematologic complications.

Special Considerations: Cross-reactivity with penicillin allergy is low but possible; third-generation cephalosporins are preferred for serious infections.

Macrolides:

Macrolides inhibit bacterial protein synthesis by binding to the 50S ribosomal subunit. They are especially useful in treating atypical respiratory infections.

Common Drugs: Azithromycin, Clarithromycin, Erythromycin.

Indications: Atypical pneumonia (*Mycoplasma pneumoniae*), pertussis, pharyngitis in penicillin-allergic children.

Pharmacokinetics: Well absorbed orally, widely distributed in tissues, metabolized in the liver.

Adverse Effects: Gastrointestinal upset, rare hepatotoxicity, cardiac arrhythmias (QT prolongation).

Special Considerations: Resistance is increasing among *S. pneumoniae* and *Mycoplasma* species; use judiciously.

Aminoglycosides:

Aminoglycosides are bactericidal antibiotics that inhibit protein synthesis by binding to the 30S ribosomal subunit. They are primarily used for serious Gram-negative infections.

Common Drugs: Gentamicin, Amikacin.

Indications: Neonatal sepsis, complicated UTIs, intra-abdominal infections.

Pharmacokinetics: Poor oral absorption; administered intravenously or intramuscularly; eliminated via kidneys.

Adverse Effects: Nephrotoxicity, ototoxicity, neuromuscular blockade in rare cases.

Special Considerations: Therapeutic drug monitoring is essential to avoid toxicity; often used in combination with beta-lactams for synergy.

Fluoroquinolones:

[10]Fluoroquinolones inhibit bacterial DNA gyrase and topoisomerase IV, leading to inhibition of DNA replication. Use in pediatrics is restricted due to potential cartilage toxicity.

Common Drugs: Ciprofloxacin, Levofloxacin.

Indications: Reserved for multidrug-resistant infections, complicated UTIs, and select hospital-acquired infections.

Pharmacokinetics: Well absorbed orally, widely distributed, hepatic and renal elimination.

Adverse Effects: Tendinopathy, arthropathy, gastrointestinal upset, rare CNS effects.

Special Considerations: Avoid in growing children unless benefits outweigh risks; monitor for musculoskeletal adverse events.

Sulfonamides:

Sulfonamides inhibit bacterial folic acid synthesis, thereby preventing DNA synthesis.

Common Drugs: Trimethoprim-Sulfamethoxazole (TMP-SMX).

Indications: UTIs, skin and soft tissue infections, prophylaxis in certain immunocompromised children.

Pharmacokinetics: Well absorbed orally, widely distributed, metabolized in the liver, excreted renally.

Adverse Effects: Rash, hyperkalemia, bone marrow suppression, kernicterus in neonates.

Special Considerations: Avoid in infants under 2 months; check for G6PD deficiency.

Summary: Each antibiotic class has specific indications, pharmacokinetics, and safety profiles that must be considered when treating pediatric patients. Proper selection helps maximize efficacy, minimize adverse effects, and reduce the risk of developing antibiotic resistance.



Figure no.2

DOSING CONSIDERATIONS

[11]Pediatric dosing of antibiotics requires careful adjustment based on the child's age, weight, organ function, and the severity of infection. Children are not simply "small adults"; pharmacokinetic differences due to immature hepatic and renal systems significantly affect drug absorption, distribution, metabolism, and excretion.

Weight-Based Dosing:

Most pediatric antibiotics are dosed according to body weight (mg/kg) to ensure therapeutic efficacy while minimizing toxicity.Accurate weight measurement is essential, and adjustments must be made regularly, especially in infants and children with rapid growth.

Age-Dependent Adjustments:

Neonates and young infants have reduced renal clearance and hepatic metabolism, requiring lower doses or extended dosing intervals.Older children may require higher doses due to increased metabolic rate and drug clearance.

Renal and Hepatic Function Monitoring:

Drugs such as aminoglycosides and vancomycin are renally excreted; impaired kidney function necessitates dose adjustment.Hepatically metabolized drugs, including macrolides and some cephalosporins, require careful monitoring in children with liver disease.

Therapeutic Drug Monitoring (TDM):

TDM is essential for drugs with narrow therapeutic windows, such as aminoglycosides, vancomycin, and some antifungals.Monitoring peak and trough levels helps optimize efficacy and prevent toxicity.

Dosing Interval and Duration:

Shorter dosing intervals may be needed for rapidly cleared drugs, while longer intervals may be appropriate for drugs with prolonged half-lives in neonates.Duration should be guided by infection type, severity, and clinical response to avoid unnecessary prolonged therapy that can promote resistance.

Route of Administration:

Oral administration is preferred when feasible for uncomplicated infections.Intravenous therapy is indicated for severe infections, systemic illness, or when oral absorption is unreliable.

Special Considerations:

Obese children may require adjusted dosing based on ideal body weight or lean body mass.Children with chronic conditions such as cystic fibrosis may require higher doses due to increased drug clearance.

Guideline-Based Adjustments:

Always follow evidence-based pediatric dosing guidelines from sources such as WHO, AAP, or local antimicrobial stewardship protocols..

ADVERSE EFFECTS OF ANTIBIOTICS

Class	Common Adverse Effects	Rare/Serious Effects
Penicillins	Rash, diarrhea	Anaphylaxis
Cephalosporins	GI upset	Hemolytic anemia
Macrolides	GI upset	QT prolongation
Aminoglycosides	Nephrotoxicity	Ototoxicity
Fluoroquinolones	GI upset	Tendon rupture
Sulfonamides	Rash	Kernicterus in neonates

Antimicrobial Resistance in Children

[14]Antimicrobial resistance (AMR) is a growing concern in pediatric populations due to widespread antibiotic use and misuse. Children are often prescribed antibiotics for viral infections or without proper microbiological confirmation, which accelerates the development of resistance. Common resistant pathogens in children include methicillin-resistant *Staphylococcus aureus* (MRSA), multidrug-resistant *Escherichia coli*, and penicillin-resistant *Streptococcus pneumoniae*. The mechanisms of resistance include the production of enzymes like beta-lactamases that degrade antibiotics, alterations in bacterial cell targets, efflux pumps that remove drugs from bacterial cells, and horizontal gene transfer between bacteria. Resistant infections lead to prolonged illness, increased hospitalizations, higher healthcare costs, and a greater risk of complications. Preventing AMR in children requires implementing effective stewardship programs, prescribing antibiotics only when necessary, choosing narrow-spectrum agents when possible, educating caregivers about appropriate use, and monitoring resistance patterns in the community and hospital settings. Rapid diagnostic tests can also help in reducing unnecessary antibiotic use by distinguishing bacterial from viral infections. Addressing antimicrobial resistance in children is critical to maintaining the efficacy of antibiotics. Judicious use, guided by clinical evidence, stewardship programs, and ongoing surveillance, is essential to slow the emergence of resistant pathogens and ensure successful treatment outcomes. Pediatric antibiotic stewardship involves a set of coordinated strategies aimed at optimizing antibiotic use to achieve the best clinical outcomes while minimizing toxicity and reducing the emergence of resistance. The primary goals of stewardship programs are to ensure appropriate selection, dosing, route, and duration of antibiotic therapy in children.

CONCLUSION

Antibiotic therapy in children is a cornerstone of pediatric healthcare, crucial for the effective management of bacterial infections. However, its use requires careful consideration due to the unique physiological characteristics of children, potential adverse effects, and the global threat of antimicrobial resistance. Proper selection of antibiotic class, dose, route, and duration, tailored to age, weight, organ function, and severity of infection, is essential to maximize therapeutic outcomes and minimize risks.The emergence of resistant pathogens highlights the urgent need for robust antimicrobial stewardship programs, rational prescribing practices, and adherence to clinical guidelines. Special populations, such as neonates, immunocompromised children, and those with chronic illnesses, require individualized approaches and close monitoring to ensure safety and efficacy.Future directions in pediatric antibiotic therapy, including pharmacogenomics, novel antibiotics, alternative therapies, rapid diagnostics, and preventive strategies like vaccination, hold promise in enhancing treatment precision, reducing adverse effects, and combating resistance. Collaboration among clinicians, pharmacists, microbiologists, and public health officials is vital to implement these strategies effectively.

References

1. Mathur, S., Fuchs, A., Bielicki, J., Van Den Anker, J., & Sharland, M. (2024). Antibiotic use for community-acquired pneumonia in neonates and children: WHO evidence review. The Lancet Infectious Diseases, 24(1), 1-12. Link
2. Meesters, K., & Patel, A. (2023). Macrolides in children: judicious use, avoiding resistance and reducing adverse effects. Archives of Disease in Childhood-Education and Practice Edition, 108(3), 121-127. Link

3. Costelloe, C., & Mantel-Teeuwisse, A. (2022). Global prevalence of antibiotic resistance in pediatric urinary tract infections caused by Escherichia coli. The Lancet Infectious Diseases, 22(4), 482-490. Link
4. World Health Organization. (2022). Antimicrobial resistance in children: Global report. Link
5. Van den Anker, J., et al. (2021). Pharmacokinetics of antibiotics in neonates and children. Clinical Pharmacokinetics, 60, 1-20.
6. Bielicki, J., et al. (2021). Optimizing antibiotic therapy in children: Pharmacokinetics, dosing, and safety. Paediatric Drugs, 23, 1-15.
7. Sharland, M., et al. (2020). Antibiotic stewardship in pediatric healthcare settings. The Pediatric Infectious Disease Journal, 39(11), 1023-1030.
8. Hsia, Y., et al. (2019). Use of antibiotics in children in 70 countries. Lancet Infectious Diseases, 19, 1036-1046.
9. McCaig, L. F., et al. (2018). Outpatient antibiotic prescribing patterns for children in the United States. JAMA Pediatrics, 172, 63-69.
10. Arshad, H., et al. (2019). Adverse drug reactions of antibiotics in pediatrics. Journal of Pediatric Pharmacology and Therapeutics, 24(5), 410-419.
11. Tamma, P. D., et al. (2020). Antimicrobial stewardship in children: Current practices and challenges. Infectious Disease Clinics of North America, 34(2), 343-360.
12. Zaoutis, T. E., et al. (2019). Antibiotic resistance trends among pediatric pathogens. Clinical Infectious Diseases, 69, 209-218.
13. Kronman, M. P., et al. (2020). Trends in pediatric antibiotic prescribing. Pediatrics, 145, e20193123.
14. Wurm, P., Curtis, N., & Zimmermann, P. The effect of antibiotics on the intestinal microbiota in children – a systematic review. PubMed
15. Atem, T. D., Singh, R., Newbury-Birch, D. et al. Prevalence and associated factors of self-medication with antibiotics among pediatric population in India: a systematic review and meta-analysis. BMC Pediatrics, 2025. BioMed Central
16. Elizondo-Alzola, U., Rocha, C., Leache, L., et al. Educational interventions and contextual factors for optimising antibiotic prescription in paediatric uncomplicated acute respiratory tract infections in primary care: scoping review of reviews. BMC Pediatrics, 2025. BioMed Central
17. The Impact of Antimicrobial Stewardship Programmes in Paediatric Emergency Departments and Primary Care: a systematic review - Brigadoi, G., Rossin, S., Visentin, D., Barbieri, E., Giaquinto, C., Da Dalt, L., Donà, D. (2023). SAGE Journals
18. Wrench, P., Curtis, N., et al. [Same as #1] — The effect of antibiotics on the intestinal microbiota in children – a systematic review. PubMed
19. Gill, E. M., Jung, K., Qvist, N., et al. Antibiotics in the medical and surgical treatment of necrotizing enterocolitis. A systematic review. BMC Pediatrics, 2022. BioMed Central
20. Efficacy of Antibiotic Regimens for Sepsis or Possible Serious Bacterial Infection in Young Infants Aged 0 to 59 Days: A Systematic Review and Meta-analysis. Pediatrics. Pediatrics Publications
21. Efficacy of Antibiotic Regimens for Pneumonia in Young Infants Aged 0-59 Days: A Systematic Review. Pediatrics. Pediatrics Publications
22. Muhammad Aaqib Shamim, Bijaya K. Padhi, Prakasini Satapathy, Abdelmonem Siddiq, Subhanwita Manna, Arun K. Aggarwal, Tareq Al-Ahdal, Jagdish Khubchandani, Andrés F. Henao-Martinez, Ranjit Sah (2023). Parents' expectation of antibiotic prescriptions for respiratory infections in children: a systematic review and meta-analysis. SAGE Journals
23. Should my child be given antibiotics? A systematic review of parental decision making in rural and remote locations. Antimicrobial Resistance & Infection Control, 2024. aricjournal.biomedcentral.com